Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.

Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments. American journal of hematology Furqan, F., Ahn, K. W., Kaur, M., Patel, J., Ansell, S., Awan, F. T., Baird, J., Bezerra, E., Farooq, U., Fung, H., Khurana, A., Lekakis, L., Lutfi, F., McCarty, J., Mukherjee, A., Nath, R., Romancik, J., Schuster, S. J., Smith, M., Winter, A., Turtle, C., Sauter, C., Shadman, M., Herrara, A., Hamadani, M. 2025

Abstract

Although recent studies have demonstrated the efficacy of chimeric antigen receptor T-cell (CAR-T) therapy in relapsed large B-cell lymphoma (LBCL) with MYC rearrangement (R-MYC), the data comparing CAR-T to autologous hematopoietic cell transplant (auto-HCT) in such patients who achieve a complete or partial response (CR/PR) after salvage therapies are limited. We compared the clinical outcomes of patients with R-MYC LBCL (including double and triple hit lymphomas) who underwent CAR-T or auto-HCT after achieving a CR/PR with salvage therapies using the Center for International Blood & Marrow Transplant Research registry. Among the 252 patients (auto-HCT?=?98, CAR-T?=?154), relative to auto-HCT, CAR-T was associated with significantly lower overall survival (OS) (Hazard Ratio [HR] 2.09, 95% CI 1.38-3.15, p?

View details for DOI 10.1002/ajh.27687

View details for PubMedID 40231369